Overview A Trial of SHR1258 in Patients With Biliary Tract Cancer Status: Not yet recruiting Trial end date: 2022-08-01 Target enrollment: Participant gender: Summary The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers Phase: Phase 2 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.